Bullous Pemphigoid Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - AstraZeneca, Akari Therapeutics, Regeneron Pharmaceuticals

(Las Vegas, Nevada, United States) DelveInsight's "DelveInsight's "Bullous Pemphigoid (BP) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the BP, historical and forecasted epidemiology as well as the BP market trends in the United States, the EU4 and the UK and Japan.

Download Sample Report to know more
@https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Bullous Pemphigoid Overview
As per the national organization of rare diseases, bullous pemphigoid (BP) is a rare, autoimmune, chronic skin disorder characterized by blistering, urticarial lesions (hives) and itching. Less commonly these blisters can involve the mucous membranes including the eyes, oral mucosa, esophagus, and genital mucosa. Moreover, it is the most common autoimmune subepidermal blistering disorder, representing 80% of subepidermal immunobullous cases. Bullous Pemphigoid most commonly affects elderly patients between the ages of 60 to 80 years. It ranges from mildly itchy welts to severe blisters and infections and may affect a small area of the body or be widespread. It is caused by autoantibodies directed against the hemidesmosomal proteins BP180 and BP230. The degree of symptoms varies, at first the skin usually becomes red and itchy. Within weeks to months, thin-walled, tense blisters with clear fluid centers (bullae) appear on the arms and legs (flexor surfaces), in the armpits (axillae), on the abdomen, and/or in the skin folds of the groin. The diagnosis is made based on a combination of clinical interpretation and laboratory findings. First, dermatologists usually suspect the diagnosis of BP in patients with itchy, red, hive-like patches, with or without blistering in elderly patients. Later, the diagnosis is confirmed by skin biopsy (a direct immunofluorescence biopsy might be needed) or Enzyme-linked immunosorbent assay (ELISA).

Click here to learn more about the Bullous Pemphigoid Market Landscape @https://www.delveinsight.com/report-store/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Highlights from Bullous Pemphigoid Market Report
According to Baigrie and Nookala (2021), BP affects individuals older than 60 years of age. The annual incidence is 6 to 13 new cases per million people in the United States, while it affects 12 to 13 per million in Central Europe. It has an equal incidence in both males and females and has no racial bias.
According to a study conducted by Harman et al. (2021), the prevalence of BP was 26·82 (95% CI 23·83-30·19) per 100,000 people in 1998 and increased to 47·99 (95% CI 43·09-53·46) per 100,000 in 2017. The most recent estimate of the prevalence of BP in those aged over 60 years was 141·24 (95% CI 125·55-158·87) per 100,000 people in 2017. In the over-80s, the prevalence was 375·02 (95% CI 320·31-439·04) per 100,000. The incidence was 7·63 [95% confidence interval (CI) 7·35-7·93] per 100 000 person-years and rose with increasing age, particularly for elderly men. The annual increase in incidence was 0·9%.
As per Aşkın et al. (2020), the most commonly observed comorbidities in bullous pemphigoid patients were hypertension in 26 patients (45%), diabetes mellitus in 14 patients (24%), coronary artery diseases in 6 patients (1%), chronic kidney disease in 4 patients (0.7%) and osteoporosis in 4 patients (0.7%). For the 58 patients included in the study the female-to-male ratio was 1.42. The average age of diagnosis was 73.79 years (15-103 years).

Bullous Pemphigoid Treatment Market
Treatment includes Topical Steroids, Oral Steroids, and Anti-inflammatory antibiotics.
Localized BP often can be treated successfully with topical steroids alone. Less than 20% of body surface area in an elderly patient, super-potent topical steroids such as clobetasol may be used. Topical steroids combined with nicotinamide plus tetracycline, minocycline, or doxycycline have shown success in multiple cases.
(prednisone, prednisolone) are the treatment of choice for severe cases. Systemic prednisone at a dose of 0.5 to 1.0mg/kg per day is recommended. This dose of systemic corticosteroids controls the disease within approximately two weeks and can be slowly tapered over six to nine months or longer. This treatment regimen is limited by patient age, comorbidities, and side effects. Potent topical corticosteroids can control generalized BP with fewer systemic side effects.
Doxycycline has been used as adjuvant therapy in BP due to its anti-inflammatory properties without overt immunosuppression. Inhibition of matrix metalloproteinases and neutrophilic activation caused by immune complex formation between IgG autoantibodies and BP antigens prevents the disruption of the dermal-epidermal junction and may contribute to disease control.

Learn more about the treatment market for Bullous Pemphigoid @ https://www.delveinsight.com/report-store/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

The Report Covers the Bullous Pemphigoid Epidemiology Segmented by:
Bullous Pemphigoid Incident cases
Bullous Pemphigoid Treated Cases
Bullous Pemphigoid Age-Specific Cases
Bullous Pemphigoid Comorbidity Associated Cases

Bullous Pemphigoid Dug Profile and Companies Covered
AstraZeneca
Akari Therapeutics
Regeneron Pharmaceuticals
And many others.

Learn more about the Key Companies and Emerging Therapies in the Bullous Pemphigoid Market @https://www.delveinsight.com/report-store/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
Key Insights
Bullous Pemphigoid Introduction
Executive Summary of Bullous Pemphigoid
Disease Background and Overview
Bullous Pemphigoid Epidemiology and patient population
Bullous Pemphigoid Emerging Therapies
Bullous Pemphigoid Market Outlook
Bullous Pemphigoid Market Access and Reimbursement of Therapies
Bullous Pemphigoid Market Drivers
Bullous Pemphigoid Market Barriers
Appendix
Bullous Pemphigoid Report Methodology
DelveInsight Capabilities
Disclaimer

Learn about the detailed offerings of the Bullous Pemphigoid Market Outlook report @ https://www.delveinsight.com/report-store/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Related Reports
Bullous Pemphigoid Epidemiology Forecast
https://www.delveinsight.com/report-store/bullous-pemphigoid-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Bullous Pemphigoid Pipeline Forecast
https://www.delveinsight.com/report-store/bullous-pemphigoid-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Trending Reports
Functional Constipation Market
https://www.delveinsight.com/report-store/functional-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market
https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Epidemiology https://www.delveinsight.com/report-store/immune-thrombocytopenic-purpura-epidemiology-forecast

Visceral Pain Associated with GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin Dependent Kinase like 5 Deficiency Disorder Market
https://www.delveinsight.com/report-store/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger Ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-Related Hearing Loss Medical Device
https://www.delveinsight.com/report-store/age-related-hearing-loss-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market
Hypoplastic Left Heart Syndrome Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/ Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market
Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market
Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive DisorderMarket
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid Lipofuscinosis Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market
Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach

This release was published on openPR.